JP2004522803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004522803A5 JP2004522803A5 JP2003508390A JP2003508390A JP2004522803A5 JP 2004522803 A5 JP2004522803 A5 JP 2004522803A5 JP 2003508390 A JP2003508390 A JP 2003508390A JP 2003508390 A JP2003508390 A JP 2003508390A JP 2004522803 A5 JP2004522803 A5 JP 2004522803A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- interferon
- composition
- interferon beta
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000014150 Interferons Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims 4
- 102220476665 Dynein axonemal assembly factor 10_S75T_mutation Human genes 0.000 claims 3
- 102000003996 Interferon-beta Human genes 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 102220519361 Coatomer subunit alpha_C17S_mutation Human genes 0.000 claims 2
- 102220466793 HLA class II histocompatibility antigen, DR beta 5 chain_L28S_mutation Human genes 0.000 claims 2
- 102220104696 rs879253900 Human genes 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102220491096 ADP-ribosylation factor 6_H97N_mutation Human genes 0.000 claims 1
- 102220627590 Coagulation factor IX_K45N_mutation Human genes 0.000 claims 1
- 102220627589 Coagulation factor IX_L20S_mutation Human genes 0.000 claims 1
- 102220576032 HLA class I histocompatibility antigen, B alpha chain_Q94S_mutation Human genes 0.000 claims 1
- 102220541980 HLA class II histocompatibility antigen, DQ beta 1 chain_Y92N_mutation Human genes 0.000 claims 1
- 102220548011 Inducible T-cell costimulator_Q10S_mutation Human genes 0.000 claims 1
- 102220520996 N-chimaerin_D54T_mutation Human genes 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 102220480985 Nicotinate phosphoribosyltransferase_Q51N_mutation Human genes 0.000 claims 1
- 102220553025 Proenkephalin-A_D39S_mutation Human genes 0.000 claims 1
- 102220516730 Protease-associated domain-containing protein 1_L21S_mutation Human genes 0.000 claims 1
- 102220486979 Sodium-dependent phosphate transport protein 1_S76N_mutation Human genes 0.000 claims 1
- 102220577394 Stromal cell-derived factor 1_K45S_mutation Human genes 0.000 claims 1
- 102220566198 Survival motor neuron protein_F70S_mutation Human genes 0.000 claims 1
- 102220603542 TYRO protein tyrosine kinase-binding protein_R27N_mutation Human genes 0.000 claims 1
- 102220603146 Transcription factor SOX-4_I59S_mutation Human genes 0.000 claims 1
- 102220472118 Transmembrane protein_Q48N_mutation Human genes 0.000 claims 1
- 102220487674 Uridine diphosphate glucose pyrophosphatase NUDT22_K19N_mutation Human genes 0.000 claims 1
- 102200094703 c.232G>A Human genes 0.000 claims 1
- 102220354160 c.245C>A Human genes 0.000 claims 1
- 102220389089 c.33G>T Human genes 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102220236328 rs1131691720 Human genes 0.000 claims 1
- 102220085575 rs140584714 Human genes 0.000 claims 1
- 102220244835 rs1554042187 Human genes 0.000 claims 1
- 102220039277 rs199473352 Human genes 0.000 claims 1
- 102220268018 rs201210997 Human genes 0.000 claims 1
- 102200037714 rs2655655 Human genes 0.000 claims 1
- 102200118184 rs33924775 Human genes 0.000 claims 1
- 102220020523 rs397508412 Human genes 0.000 claims 1
- 102200080720 rs4077515 Human genes 0.000 claims 1
- 102220014798 rs56204273 Human genes 0.000 claims 1
- 102220035775 rs587779734 Human genes 0.000 claims 1
- 102200027869 rs62517167 Human genes 0.000 claims 1
- 102200087964 rs63751258 Human genes 0.000 claims 1
- 102200021380 rs727504457 Human genes 0.000 claims 1
- 102220232854 rs766277488 Human genes 0.000 claims 1
- 102220312163 rs772475317 Human genes 0.000 claims 1
- 102220018673 rs80358415 Human genes 0.000 claims 1
- 102220137564 rs886055455 Human genes 0.000 claims 1
- -1 sulfoalkyl ether cyclodextrin derivative Chemical class 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101040 | 2001-06-29 | ||
| DKPA200101277 | 2001-08-30 | ||
| DKPA200200257 | 2002-02-19 | ||
| PCT/DK2002/000444 WO2003002152A2 (en) | 2001-06-29 | 2002-06-28 | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004522803A JP2004522803A (ja) | 2004-07-29 |
| JP2004522803A5 true JP2004522803A5 (enExample) | 2006-01-05 |
Family
ID=27222516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003508390A Withdrawn JP2004522803A (ja) | 2001-06-29 | 2002-06-28 | インターフェロン製剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1414498A2 (enExample) |
| JP (1) | JP2004522803A (enExample) |
| CN (1) | CN1522159A (enExample) |
| CA (1) | CA2452364A1 (enExample) |
| MX (1) | MXPA03011793A (enExample) |
| RU (1) | RU2004102500A (enExample) |
| WO (1) | WO2003002152A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7959910B2 (en) | 2000-07-31 | 2011-06-14 | Biolex Therapeutics, Inc. | C-terminally truncated interferon alpha variants |
| AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| US20040126360A1 (en) * | 2002-10-09 | 2004-07-01 | Manning Mark C. | Oral formulations for proteins and polypeptides |
| RS20050502A (sr) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću |
| US7846427B2 (en) | 2003-12-11 | 2010-12-07 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| BRPI0510527A (pt) * | 2004-06-01 | 2007-10-30 | Ares Trading Sa | método de estabilização de proteìnas |
| US20070212306A1 (en) * | 2004-06-07 | 2007-09-13 | Quay Steven C | Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides |
| US20060024272A1 (en) * | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| SG155183A1 (en) * | 2005-08-26 | 2009-09-30 | Ares Trading Sa | Process for the preparation of glycosylated interferon beta |
| US20070243163A1 (en) * | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
| WO2007101949A2 (fr) * | 2006-03-08 | 2007-09-13 | Biomethodes | Variants de l'interferon- gamma humain (infgamma) |
| JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| MX2009011619A (es) * | 2007-04-27 | 2010-01-18 | Cydex Pharmaceuticals Inc | Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| ES2387236T3 (es) | 2007-12-20 | 2012-09-18 | Merck Serono S.A. | Formulaciones de interferón beta pegilado |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| AR074357A1 (es) * | 2008-11-17 | 2011-01-12 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro |
| KR101743591B1 (ko) | 2009-05-13 | 2017-06-20 | 사이덱스 파마슈티칼스, 인크. | 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법 |
| RU2482871C2 (ru) * | 2010-06-07 | 2013-05-27 | Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") | Композиция для лечения вирусных заболеваний животных |
| SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| US10012064B2 (en) | 2015-04-09 | 2018-07-03 | Highlands Natural Resources, Plc | Gas diverter for well and reservoir stimulation |
| US10344204B2 (en) | 2015-04-09 | 2019-07-09 | Diversion Technologies, LLC | Gas diverter for well and reservoir stimulation |
| IL299759A (en) | 2015-12-30 | 2023-03-01 | Genentech Inc | Formulations with reduced polysorbate dissolution |
| US10982520B2 (en) | 2016-04-27 | 2021-04-20 | Highland Natural Resources, PLC | Gas diverter for well and reservoir stimulation |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| JP7105200B2 (ja) * | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | 標的突然変異体インターフェロン－ベータおよびその使用 |
| CA3108066A1 (en) * | 2018-07-30 | 2020-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Interferon-gamma biased agonists |
| CN111358938B (zh) * | 2020-03-30 | 2023-08-11 | 温州肯恩大学(Wenzhou-KeanUniversity) | 人干扰素-ε与干扰素-γ组合药及用途 |
| CN113797317B (zh) * | 2021-10-26 | 2024-01-09 | 科兴生物制药股份有限公司 | 一种组合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6133248A (en) * | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
-
2002
- 2002-06-28 JP JP2003508390A patent/JP2004522803A/ja not_active Withdrawn
- 2002-06-28 MX MXPA03011793A patent/MXPA03011793A/es unknown
- 2002-06-28 EP EP02748632A patent/EP1414498A2/en not_active Withdrawn
- 2002-06-28 CA CA002452364A patent/CA2452364A1/en not_active Abandoned
- 2002-06-28 CN CNA028131215A patent/CN1522159A/zh active Pending
- 2002-06-28 WO PCT/DK2002/000444 patent/WO2003002152A2/en not_active Ceased
- 2002-06-28 RU RU2004102500/15A patent/RU2004102500A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004522803A5 (enExample) | ||
| US8633157B2 (en) | Glycopegylated erythropoietin | |
| KR101439880B1 (ko) | 펩티드의 오-결합형 글리코실화 | |
| US8268967B2 (en) | Glycopegylated interferon α | |
| US9029331B2 (en) | Glycopegylated granulocyte colony stimulating factor | |
| JP2004534523A5 (enExample) | ||
| US20080015142A1 (en) | Glycopegylated Follicle Stimulating Hormone | |
| WO2002020766A3 (en) | G-csf analog compositions and methods | |
| YU48703A (sh) | Novi interferonu beta-slični molekuli | |
| DE60332358D1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| DE69501001D1 (de) | Stärke modifiziert durch Amino-Polycarboxylaten | |
| MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
| AU3808700A (en) | Compositions and methods for recombinant adeno-associated virus production | |
| MXPA03011793A (es) | Formulaciones de interferon. | |
| EP1636248A4 (en) | HUMAN CHONDROITINASE GLYCOPROTEIN (CHASEGP), PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID GLYCOPROTEIN | |
| AU2002330289A1 (en) | Preparation of a therapeutic composition | |
| WO2002098346A3 (en) | Method and pharmaceutical composition for the treatment of multiple sclerosis | |
| AU3662593A (en) | Pulmonary surfactant protein fragments | |
| WO2003075944A2 (en) | Interferon beta-like molecules for treatment of stroke | |
| NO20060675L (no) | Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider | |
| TWI256388B (en) | Pharmaceutical combination | |
| DE60236441D1 (de) | Alpha-1,2-fucosyl-transferase und diese codierende dna | |
| MXPA04002517A (es) | Composiciones para el control del apetito y metodos relacionados. | |
| WO2004033696A3 (fr) | Vecteurs adenoviraux recombinants et leurs applications | |
| AU2000263446A1 (en) | Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene |